Daniel Arber to Myelodysplastic-Myeloproliferative Diseases
This is a "connection" page, showing publications Daniel Arber has written about Myelodysplastic-Myeloproliferative Diseases.
Connection Strength
1.862
-
Classification of Myelodysplastic, Myeloproliferative, and Myelodysplastic/Myeloproliferative Neoplasms: The Past, Present, and Future. Am J Hematol. 2025 Jun; 100 Suppl 4:5-15.
Score: 0.934
-
Role of allo-HCT in "nonclassical" MPNs and MDS/MPNs: recommendations from the PH&G Committee and the CMWP of the EBMT. Blood. 2025 May 29; 145(22):2561-2573.
Score: 0.237
-
Advances in myelodysplastic/myeloproliferative neoplasms. Virchows Arch. 2023 Jan; 482(1):69-83.
Score: 0.200
-
EAHP 2020 workshop proceedings, pediatric myeloid neoplasms. Virchows Arch. 2022 Oct; 481(4):621-646.
Score: 0.194
-
Chronic myeloid neoplasms harboring concomitant mutations in myeloproliferative neoplasm driver genes (JAK2/MPL/CALR) and SF3B1. Mod Pathol. 2021 01; 34(1):20-31.
Score: 0.169
-
Atypical chronic myeloid leukemia is clinically distinct from unclassifiable myelodysplastic/myeloproliferative neoplasms. Blood. 2014 Apr 24; 123(17):2645-51.
Score: 0.109
-
The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood. 2009 Jul 30; 114(5):937-51.
Score: 0.019